What is Mvasi (bevacizumab-awwb) and how is it used to treat colon cancer?

Updated: Apr 15, 2020
  • Author: Tomislav Dragovich, MD, PhD; Chief Editor: N Joseph Espat, MD, MS, FACS  more...
  • Print

In September 2017, the FDA approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab), to be used in combination with fluoropyrimidine-irinotecan– or fluoropyrimidine-oxaliplatin–based chemotherapy for the second-line treatment of patients with metastatic colorectal cancer who have progressed on a first-line bevacizumab-product–containing regimen. The approval was based on evidence from animal study data, human pharmacokinetic and pharmacodynamics data, and clinical immunogenicity data that supported Mvasi as a biosimilar to Avastin. [107]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!